I think, the Nadolol -Zafirlukast development combo alone is worth a capitalisation at these levels. Invion were happy to go into more debt to get Zafirlukast. I feel these are slam dunks for Dr Glass hence the willingness to expand at a time when the company is quite cash poor. Its just a matter of time with these proven drugs (dyor).
CPN10 is the big wildcard here. There are still 1 or 2 key people from cbio days in Invion (see Linked In). I have no doubt that with the right trial, and hopefully that's Lupus, we'll see a bright LED at the end of a dark tunnel.
Short term issues - looks like the Smok Cess study still has not started recruiting and it should have really started in Feb if i remember from the Jan press release. I wonder what the hold up is. Re-titration of nadolol? surely thats not an issue? maybe there is impatience on this score. I'd like the company to clarify because its all smoke and mirrors LOL.
IVX Price at posting:
7.1¢ Sentiment: Buy Disclosure: Held
A personalised tool to help users track selected stocks. Delivering real-time notifications on price updates, announcements, and performance stats on each to help make informed investment decisions.
(20min delay)